4-{2-[4-(Benzo[1,3]dioxole-5-sulfonyl)-phenyl]-[1,3]dioxolan-2-yl}-1'-(propane-1-sulfonyl)-[1,4']bipiperidinyl

ID: ALA76164

Chembl Id: CHEMBL76164

PubChem CID: 9916852

Max Phase: Preclinical

Molecular Formula: C29H38N2O8S2

Molecular Weight: 606.76

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CCCS(=O)(=O)N1CCC(N2CCC(C3(c4ccc(S(=O)(=O)c5ccc6c(c5)OCO6)cc4)OCCO3)CC2)CC1

Standard InChI:  InChI=1S/C29H38N2O8S2/c1-2-19-40(32,33)31-15-11-24(12-16-31)30-13-9-23(10-14-30)29(38-17-18-39-29)22-3-5-25(6-4-22)41(34,35)26-7-8-27-28(20-26)37-21-36-27/h3-8,20,23-24H,2,9-19,21H2,1H3

Standard InChI Key:  RZONVHYKSUHFCL-UHFFFAOYSA-N

Associated Targets(Human)

CHRM2 Tclin Muscarinic acetylcholine receptor M2 (10671 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHRM1 Tclin Muscarinic acetylcholine receptors; M1 & M2 (498 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHRM3 Tclin Muscarinic acetylcholine receptors; M2 & M3 (708 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 606.76Molecular Weight (Monoisotopic): 606.2070AlogP: 3.36#Rotatable Bonds: 8
Polar Surface Area: 111.68Molecular Species: NEUTRALHBA: 9HBD:
#RO5 Violations: 1HBA (Lipinski): 10HBD (Lipinski): #RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 7.24CX LogP: 2.92CX LogD: 2.69
Aromatic Rings: 2Heavy Atoms: 41QED Weighted: 0.45Np Likeness Score: -0.80

References

1. Boyle CD, Chackalamannil S, Clader JW, Greenlee WJ, Josien HB, Kaminski JJ, Kozlowski JA, McCombie SW, Nazareno DV, Tagat JR, Wang Y, Zhou G, Billard W, Binch H, Crosby G, Cohen-Williams M, Coffin VL, Cox KA, Grotz DE, Duffy RA, Ruperto V, Lachowicz JE..  (2001)  Metabolic stabilization of benzylidene ketal M(2) muscarinic receptor antagonists via halonaphthoic acid substitution.,  11  (17): [PMID:11527721] [10.1016/s0960-894x(01)00435-8]
2. Boyle CD, Chackalamannil S, Chen LY, Dugar S, Pushpavanam P, Billard W, Binch H, Crosby G, Cohen-Williams M, Coffin VL, Duffy RA, Ruperto V, Lachowicz JE..  (2000)  Benzylidene ketal derivatives as M2 muscarinic receptor antagonists.,  10  (24): [PMID:11133078] [10.1016/s0960-894x(00)00553-9]
3. Wu YJ, Meanwell NA..  (2021)  Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design.,  64  (14.0): [PMID:34213340] [10.1021/acs.jmedchem.1c00790]

Source